Long-lasting treatment suppresses HIV in people with mental illness and other conditions that make it challenging to adhere to standard treatments.

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

The researchers reported that step 2 randomization was stopped early due to the superiority of cabotegravir-rilpivirine to standard care at a prespecified analysis. HealthDay News — Monthly injections ...

Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...

Pfizer hopes to differentiate itself in the obesity drug market with a once-monthly injection. The company plans to advance 20+ obesity therapy clinical studies in 2026. Pfizer's first potential ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...

The MarketWatch News Department was not involved in the creation of this content. -- VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 ...